Multiple immortalized, malignant, human, adult prostate epithelial cell lines useful as models in epithelial cell oncogenesis studies and in the diagnosis and treatment of prostate cancer

The National Institutes of Health has multiple immortalized, malignant, human, adult prostate epithelial cell lines available for license. They are useful as models in epithelial cell oncogenesis studies and in the diagnosis and treatment of prostate cancer.

The cell lines were generated from primary adenocarcinomas of the prostate. Long-term cultures were established by immortalizing cells with human papillomavirus (HPV) transforming proteins. The cultures were characterized and single-cell clones with unique genetic characteristics were selected based on allelic loss of heterozygosity (LOH). Tissue-matched normal cell lines are available also, useful for the appropriate controls.

The invention also encompasses polyclonal and monoclonal antibodies directed to the cell lines, which may be useful as immunotherapeutics.

Applications:

• Screening tool to identify novel genes unique to or overexpressed in prostate cancer
• Raising of prostate cancer-reactive antibodies, useful as immunotherapeutics or diagnostics
• Screen for compounds that kill tumor cells and represent potential therapeutic agents
• Identification of prostate cancer antigens to develop recombinant prostate cancer vaccines

Publication:
RK Bright et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res. 1997 Mar 5;57(5):995-1002.  [PubMed abs]

U.S. Patent 6,982,168 issued on 03 Jan 2006 (HHS Reference No. E-053-1996/0-US-03)

Inventors:
Susan L. Topalian, W. Marston Linehan, Robert K. Bright, Cathy D. Vocke (NCI)

Licensees Sought:
Available for non-exclusive internal use and biological material license.

Collaborative Research Opportunity:
The NCI Center for Cancer Research, Surgery Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact John D. Hewes, Ph.D., at 301-435-3121 or hewesj@mail.nih.gov for more information.